EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Characteristics and Treatment of Juvenile Myasthenia Gravis—A Single-Center Experience

Mikiko Maeda, Hideki Shimomura iD, Sachi Tokunaga, Naoko Taniguchi, Tomoko Lee, Yasuhiro Takeshima iD

Children · 09.05.2024 · 11 (5) · 572

DOI: 10.3390/children11050572 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Children, online erschienen am 09.05.2024. Verfasst von Mikiko Maeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile myasthenia gravis (MG) is a rare autoimmune neuromuscular disease, often treated with anticholinesterases, corticosteroids, and immunosuppressants. However, optimal treatment durations remain unclear. This study investigated the clinical characteristics and treatment of juvenile MG, including medication duration. The administration period for all drugs, immunosuppressants, and prednisolone at doses greater than 0.35 mg/kg daily was extracted retrospectively from medical records. Nineteen participants (8 boys, 11 girls) aged 8 months to 14 years (median, 2.5 years) at onset were identified. Fourteen patients (73.7%) had ocular MG and five (26.3%) had generalized MG. Drug treatment was conducted in 18 cases; however, 7 patients did not complete the treatment. Among the patients who completed drug treatment, the duration of treatment ranged from 11 to 100 months (median, 47 months). In the six patients treated with continuous administration of prednisolone or immunosuppressants, the treatment duration ranged from 33 to 99 months (median, 56 months). No severe adverse effects requiring hospitalization were reported. The patients treated with prednisolone or immunosuppressants required at least 33 months of treatment. These results will help develop protocols for juvenile MG treatment.

Schlagwörter

Stichwörter der Autor:innen

drug treatmentimmunosuppressantsjuvenile myasthenia gravisoutcomeprednisolone

Autor:innen und Institutionen

  • Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan.

ORCID-Profile: Hideki Shimomura, Yasuhiro Takeshima

Zitieren

APA

Maeda, M., Shimomura, H., Tokunaga, S., Taniguchi, N., Lee, T., & Takeshima, Y. (2024). Clinical Characteristics and Treatment of Juvenile Myasthenia Gravis—A Single-Center Experience. Children, 11(5), 572. https://doi.org/10.3390/children11050572

Vancouver

Maeda M, Shimomura H, Tokunaga S, Taniguchi N, Lee T, Takeshima Y. Clinical Characteristics and Treatment of Juvenile Myasthenia Gravis—A Single-Center Experience. Children. 2024;11(5):572. doi:10.3390/children11050572

BibTeX
@article{Maeda2024,
  author = {Maeda, Mikiko and Shimomura, Hideki and Tokunaga, Sachi and Taniguchi, Naoko and Lee, Tomoko and Takeshima, Yasuhiro},
  title = {Clinical Characteristics and Treatment of Juvenile Myasthenia Gravis—A Single-Center Experience},
  journal = {Children},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {572},
  doi = {10.3390/children11050572}
}
Kostenlos starten →